BioXcel Therapeutics IncNASDAQ:BTAI
- LAST PRICE18.9300
- TODAY'S CHANGE (%)0.7800 (4.2975%)
- Bid / Lots17.6000/ 1
- Ask / Lots19.0000/ 1
- Open / Previous Close18.8600 / 18.1500
- Day Range
- 52 Week Range
- Volume629,440
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | BTAI |
|---|---|---|
| 09:32 ET | 3852 | 18.3 |
| 09:34 ET | 2000 | 18.2336 |
| 09:36 ET | 500 | 18.5 |
| 09:38 ET | 300 | 18.285 |
| 09:39 ET | 100 | 18.22 |
| 09:41 ET | 1815 | 18.17 |
| 09:48 ET | 50100 | 18.075 |
| 09:52 ET | 600 | 18.07 |
| 09:54 ET | 993 | 18.02 |
| 09:56 ET | 900 | 17.88 |
| 09:57 ET | 300 | 17.87 |
| 09:59 ET | 857 | 17.78 |
| 10:03 ET | 100 | 17.785 |
| 10:06 ET | 895 | 17.9765 |
| 10:08 ET | 403 | 17.945 |
| 10:10 ET | 4803 | 17.66 |
| 10:12 ET | 400 | 17.7 |
| 10:14 ET | 16889 | 17.75 |
| 10:15 ET | 1683 | 17.75 |
| 10:17 ET | 420 | 17.8762 |
| 10:19 ET | 386 | 17.84 |
| 10:21 ET | 1250 | 17.765 |
| 10:24 ET | 329 | 17.76 |
| 10:26 ET | 669 | 17.77 |
| 10:28 ET | 1396 | 17.98 |
| 10:30 ET | 100 | 18 |
| 10:32 ET | 1390 | 18.08 |
| 10:33 ET | 803 | 18 |
| 10:35 ET | 950 | 17.9 |
| 10:39 ET | 1055 | 17.99 |
| 10:42 ET | 550 | 18.07 |
| 10:44 ET | 2200 | 18.07 |
| 10:46 ET | 14835 | 18.24 |
| 10:50 ET | 200 | 18.085 |
| 10:51 ET | 1350 | 18.04 |
| 10:53 ET | 5604 | 18.1 |
| 10:55 ET | 2419 | 18.17 |
| 10:57 ET | 11459 | 18.24 |
| 11:00 ET | 700 | 18.23 |
| 11:02 ET | 100 | 18.2 |
| 11:04 ET | 100 | 18.17 |
| 11:06 ET | 3099 | 18.22 |
| 11:08 ET | 100 | 18.22 |
| 11:09 ET | 1500 | 18.3 |
| 11:11 ET | 1600 | 18.27 |
| 11:13 ET | 1534 | 18.32 |
| 11:15 ET | 816 | 18.28 |
| 11:18 ET | 2100 | 18.25 |
| 11:20 ET | 317 | 18.28 |
| 11:22 ET | 3717 | 18.31 |
| 11:24 ET | 1432 | 18.36 |
| 11:26 ET | 600 | 18.27 |
| 11:29 ET | 2470 | 18.24 |
| 11:31 ET | 3207 | 18.31 |
| 11:33 ET | 100 | 18.31 |
| 11:36 ET | 300 | 18.29 |
| 11:38 ET | 1734 | 18.31 |
| 11:42 ET | 4469 | 18.34 |
| 11:44 ET | 1400 | 18.31 |
| 11:45 ET | 100 | 18.33 |
| 11:47 ET | 5400 | 18.28 |
| 11:51 ET | 5790 | 18.18 |
| 11:54 ET | 411 | 18.18 |
| 11:56 ET | 600 | 18.1323 |
| 11:58 ET | 200 | 18.155 |
| 12:00 ET | 100 | 18.155 |
| 12:02 ET | 676 | 18.14 |
| 12:03 ET | 100 | 18.12 |
| 12:05 ET | 1700 | 18.22 |
| 12:09 ET | 200 | 18.2 |
| 12:12 ET | 200 | 18.21 |
| 12:16 ET | 200 | 18.23 |
| 12:18 ET | 100 | 18.2 |
| 12:20 ET | 2471 | 18.275 |
| 12:21 ET | 620 | 18.33 |
| 12:23 ET | 100 | 18.31 |
| 12:25 ET | 100 | 18.3 |
| 12:27 ET | 500 | 18.29 |
| 12:30 ET | 792 | 18.36 |
| 12:32 ET | 600 | 18.31 |
| 12:34 ET | 1300 | 18.37 |
| 12:36 ET | 400 | 18.36 |
| 12:38 ET | 600 | 18.35 |
| 12:39 ET | 400 | 18.32 |
| 12:41 ET | 200 | 18.32 |
| 12:43 ET | 1429 | 18.33 |
| 12:45 ET | 1900 | 18.41 |
| 12:48 ET | 259 | 18.34 |
| 12:50 ET | 400 | 18.29 |
| 12:52 ET | 500 | 18.3 |
| 12:54 ET | 600 | 18.31 |
| 12:57 ET | 600 | 18.33 |
| 01:01 ET | 495 | 18.33 |
| 01:03 ET | 300 | 18.33 |
| 01:06 ET | 800 | 18.35 |
| 01:08 ET | 600 | 18.32 |
| 01:10 ET | 700 | 18.3 |
| 01:12 ET | 200 | 18.3 |
| 01:14 ET | 600 | 18.33 |
| 01:15 ET | 200 | 18.3 |
| 01:17 ET | 600 | 18.33 |
| 01:19 ET | 100 | 18.33 |
| 01:21 ET | 1201 | 18.37 |
| 01:24 ET | 600 | 18.425 |
| 01:26 ET | 900 | 18.38 |
| 01:28 ET | 400 | 18.33 |
| 01:30 ET | 1000 | 18.43 |
| 01:32 ET | 400 | 18.39 |
| 01:33 ET | 500 | 18.405 |
| 01:35 ET | 500 | 18.42 |
| 01:37 ET | 300 | 18.35 |
| 01:39 ET | 300 | 18.39 |
| 01:42 ET | 500 | 18.33 |
| 01:44 ET | 602 | 18.36 |
| 01:46 ET | 1200 | 18.4 |
| 01:48 ET | 300 | 18.33 |
| 01:50 ET | 546 | 18.34 |
| 01:51 ET | 300 | 18.38 |
| 01:53 ET | 200 | 18.36 |
| 01:55 ET | 1300 | 18.4 |
| 01:57 ET | 1100 | 18.37 |
| 02:00 ET | 200 | 18.376 |
| 02:04 ET | 5281 | 18.34 |
| 02:06 ET | 100 | 18.3 |
| 02:08 ET | 1798 | 18.32 |
| 02:09 ET | 718 | 18.35 |
| 02:11 ET | 1453 | 18.37 |
| 02:13 ET | 900 | 18.43 |
| 02:15 ET | 300 | 18.39 |
| 02:18 ET | 300 | 18.45 |
| 02:20 ET | 7338 | 18.575 |
| 02:22 ET | 1498 | 18.66 |
| 02:24 ET | 4256 | 18.72 |
| 02:26 ET | 400 | 18.7575 |
| 02:27 ET | 2015 | 18.7936 |
| 02:29 ET | 300 | 18.805 |
| 02:33 ET | 3011 | 18.85 |
| 02:36 ET | 1200 | 18.75 |
| 02:38 ET | 800 | 18.72 |
| 02:40 ET | 200 | 18.665 |
| 02:42 ET | 100 | 18.665 |
| 02:44 ET | 1200 | 18.77 |
| 02:45 ET | 100 | 18.71 |
| 02:47 ET | 100 | 18.73 |
| 02:49 ET | 400 | 18.73 |
| 02:51 ET | 900 | 18.72 |
| 02:54 ET | 10594 | 18.74 |
| 02:56 ET | 400 | 18.72 |
| 02:58 ET | 1200 | 18.8 |
| 03:00 ET | 100 | 18.77 |
| 03:02 ET | 2800 | 18.745 |
| 03:03 ET | 1200 | 18.78 |
| 03:05 ET | 800 | 18.725 |
| 03:07 ET | 700 | 18.71 |
| 03:09 ET | 300 | 18.73 |
| 03:12 ET | 100 | 18.72 |
| 03:14 ET | 701 | 18.79 |
| 03:16 ET | 400 | 18.76 |
| 03:18 ET | 5012 | 18.8 |
| 03:20 ET | 600 | 18.82 |
| 03:21 ET | 2798 | 18.82 |
| 03:23 ET | 1400 | 18.85 |
| 03:25 ET | 3217 | 18.87 |
| 03:27 ET | 1317 | 18.78 |
| 03:30 ET | 1500 | 18.8 |
| 03:32 ET | 1900 | 18.79 |
| 03:34 ET | 1000 | 18.81 |
| 03:36 ET | 2900 | 18.81 |
| 03:38 ET | 2956 | 18.87 |
| 03:39 ET | 2300 | 18.875 |
| 03:41 ET | 2300 | 18.925 |
| 03:43 ET | 2900 | 18.93 |
| 03:45 ET | 2150 | 18.93 |
| 03:48 ET | 3293 | 18.895 |
| 03:50 ET | 2592 | 18.92 |
| 03:52 ET | 3411 | 18.9 |
| 03:54 ET | 5299 | 18.87 |
| 03:56 ET | 14040 | 18.9 |
| 03:57 ET | 22219 | 18.93 |
| 03:59 ET | 128453 | 18.93 |
Jun 1, 2023
BioXcel Therapeutics to Participate at Two Upcoming Investor Conferences, from 7:00AM ET on Thursday Jun 01, 2023 by GlobeNewswire
7:00AM ET on Thursday Jun 01, 2023 by GlobeNewswire
May 26, 2023
Goldman Sachs Adjusts Price Target on BioXcel Therapeutics to $25 From $28, Maintains Neutral Rating, from 10:01AM ET on Friday May 26, 2023 by MT Newswires
10:01AM ET on Friday May 26, 2023 by MT Newswires
May 25, 2023
BioXcel Therapeutics Reports Mixed Results in BXCL501 Trial for At-Home Use; Shares Drop, from 3:11PM ET on Thursday May 25, 2023 by MT Newswires
3:11PM ET on Thursday May 25, 2023 by MT NewswiresBRIEF-Bioxcel Therapeutics Announces Promising Topline Results From Part 1 Of Pivotal Serenity Iii Trial Of Bxcl501 For At-Home Use In Acute Treatment Of Agitation In Bipolar Disorders Or Schizophrenia, from 7:50AM ET on Thursday May 25, 2023 by Thomson Reuters
7:50AM ET on Thursday May 25, 2023 by Thomson ReutersBioXcel Therapeutics Announces Promising Topline Results from Part 1 of Pivotal SERENITY III Trial of BXCL501 for At-Home Use in Acute Treatment of Agitation in Bipolar Disorders or Schizophrenia, from 7:00AM ET on Thursday May 25, 2023 by GlobeNewswire
7:00AM ET on Thursday May 25, 2023 by GlobeNewswire
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
BioXcel Therapeutics Inc | 552.0M | -2.9x | --- |
Lexicon Pharmaceuticals Inc | 520.3M | -4.4x | --- |
IGM Biosciences Inc | 587.5M | -2.6x | --- |
Tenaya Therapeutics Inc | 510.9M | -3.1x | --- |
Mineralys Therapeutics Inc | 601.4M | 0.0x | --- |
Janux Therapeutics Inc | 571.9M | -8.5x | --- |
Company Information
BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The Company’s commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. BXCL501 is also being developed for the acute treatment of agitation associated with Alzheimer’s disease, and as an adjunctive treatment for major depressive disorder. The Company is also developing BXCL502 as a potential therapy for chronic agitation in dementia. Under its subsidiary, OnkosXcel Therapeutics, LLC, the Company is developing BXCL701, an investigational, oral innate immune activator that is being developed as a potential therapy for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors.
Contact Information
- Headquarters
- 555 Long Wharf DrNEW HAVEN, CT, United States 06511-6107
- Phone
- 203-643-8060
- Fax
- 302-636-5454
Executives
- Independent Chairman of the Board
- Peter Mueller
- President, Chief Executive Officer, Director
- Vimal Mehta
- Chief Financial Officer, Senior Vice President
- Richard Steinhart
- Senior Vice President, Chief Scientific Officer
- Frank Yocca
- Senior Vice President, Chief Legal Officer, Corporate Secretary
- Javier Rodriguez
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $552.0M |
|---|---|
Revenue (TTM) | $581.0K |
Shares Outstanding | 29.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.08 |
EPS | $-6.64 |
Book Value | $2.73 |
P/E Ratio | -2.9x |
Price/Sales (TTM) | 950.1 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -30,872.63% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
